Q1 Earnings Estimate for Genmab A/S Issued By William Blair

Genmab A/S (NASDAQ:GMAB - Free Report) - Research analysts at William Blair dropped their Q1 2025 earnings estimates for shares of Genmab A/S in a research report issued on Monday, April 14th. William Blair analyst M. Phipps now anticipates that the company will post earnings of $0.17 per share for the quarter, down from their previous estimate of $0.28. William Blair currently has a "Outperform" rating on the stock. The consensus estimate for Genmab A/S's current full-year earnings is $1.45 per share.

A number of other research analysts also recently commented on the company. Truist Financial lowered their price objective on Genmab A/S from $50.00 to $45.00 and set a "buy" rating for the company in a research note on Tuesday, March 11th. Leerink Partners upgraded Genmab A/S from a "market perform" rating to an "outperform" rating and set a $27.00 target price on the stock in a research report on Thursday, February 13th. Leerink Partnrs raised Genmab A/S from a "hold" rating to a "strong-buy" rating in a research note on Thursday, February 13th. HC Wainwright reissued a "buy" rating and issued a $37.00 price target (down previously from $50.00) on shares of Genmab A/S in a research note on Wednesday, April 9th. Finally, Sanford C. Bernstein cut shares of Genmab A/S from a "market perform" rating to an "underperform" rating in a research note on Tuesday, April 1st. One investment analyst has rated the stock with a sell rating, three have given a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $39.17.

Genmab A/S Stock Up 0.2 %

Shares of NASDAQ:GMAB traded up $0.04 on Wednesday, reaching $20.08. 230,281 shares of the company's stock were exchanged, compared to its average volume of 1,035,180. The business's 50-day moving average is $20.54 and its two-hundred day moving average is $21.14. Genmab A/S has a fifty-two week low of $17.24 and a fifty-two week high of $30.41. The firm has a market capitalization of $13.29 billion, a price-to-earnings ratio of 11.54, a PEG ratio of 2.65 and a beta of 1.07.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last issued its earnings results on Wednesday, February 12th. The company reported $0.57 EPS for the quarter, topping the consensus estimate of $0.28 by $0.29. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%.

Hedge Funds Weigh In On Genmab A/S

Hedge funds have recently made changes to their positions in the business. EverSource Wealth Advisors LLC boosted its holdings in Genmab A/S by 295.3% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company's stock worth $26,000 after buying an additional 939 shares in the last quarter. Lindbrook Capital LLC grew its stake in Genmab A/S by 105.4% during the 4th quarter. Lindbrook Capital LLC now owns 1,851 shares of the company's stock valued at $39,000 after acquiring an additional 950 shares in the last quarter. GAMMA Investing LLC increased its stake in Genmab A/S by 96.6% in the 4th quarter. GAMMA Investing LLC now owns 2,139 shares of the company's stock valued at $45,000 after buying an additional 1,051 shares during the period. Barclays PLC increased its stake in shares of Genmab A/S by 1,072.8% in the fourth quarter. Barclays PLC now owns 2,498 shares of the company's stock worth $52,000 after acquiring an additional 2,285 shares during the last quarter. Finally, Cromwell Holdings LLC raised its holdings in shares of Genmab A/S by 656.8% during the fourth quarter. Cromwell Holdings LLC now owns 2,876 shares of the company's stock worth $60,000 after acquiring an additional 2,496 shares in the last quarter. Institutional investors and hedge funds own 7.07% of the company's stock.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.